| 1 |
34856074 | Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment. | 2022 Mar |
1 |
| 2 |
31804471 | Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach. | 2019 Dec 5 |
1 |
| 3 |
29348467 | Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. | 2018 Jan 18 |
1 |
| 4 |
29945997 | Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. | 2018 Oct 1 |
1 |
| 5 |
30021885 | PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. | 2018 Jul 18 |
1 |
| 6 |
28938614 | Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. | 2017 Aug 29 |
2 |
| 7 |
25541062 | AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. | 2015 Mar 1 |
2 |
| 8 |
22425996 | A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. | 2012 Mar 18 |
3 |